John Greene Purchases 7,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) Director John Greene acquired 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the acquisition, the director now owns 7,000 shares in the company, valued at approximately $313,950. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded up $0.30 during midday trading on Friday, reaching $43.92. The stock had a trading volume of 1,658,786 shares, compared to its average volume of 2,347,561. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $89.88. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of -10.05 and a beta of 1.67. The firm’s fifty day simple moving average is $42.42 and its two-hundred day simple moving average is $45.97.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC lifted its position in shares of CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after purchasing an additional 1,474,439 shares in the last quarter. Capital International Investors increased its stake in CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after buying an additional 816,789 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock worth $150,029,000 after buying an additional 1,074,238 shares in the last quarter. State Street Corp boosted its stake in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after buying an additional 599,304 shares during the period. Finally, FMR LLC grew its holdings in shares of CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after acquiring an additional 23,075 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on CRSP shares. Royal Bank of Canada decreased their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday, February 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. The Goldman Sachs Group lowered their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective on the stock in a research note on Wednesday, February 12th. Finally, Bank of America dropped their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $74.40.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.